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Abstract 
 
Purpose of review: Gabapentinoids are frequently used in the management of cancer pain. In recent 
Cochrane systematic reviews, whilst there was an abundance of evidence relating to non-cancer 
pain, only a few studies related to cancer pain. This review summarises recent randomised 
controlled trials evaluating the use of gabapentinoids for tumour-related (as monotherapy or part of 
combination therapy) and treatment-related pain. 
Recent findings: For tumour-related pain, 10 out of 13 studies showed statistically significant 
benefits in favour of gabapentinoids. When used, as part of monotherapy or combination therapy, 
benefits were observed in 5 out of 6 studies evaluating gabapentin, and in 6 out of 8 studies 
evaluating pregabalin. For treatment-related pain, none of the 4 studies (2 gabapentin, 2 pregabalin) 
showed statistically significant benefits in favour of gabapentinoids. Unfortunately many of the 
studies included were limited by small sample size, lack of blinding and inadequate follow-up. 
Summary: More and better quality studies are required, although this may be challenging to 
accomplish in this patient population. Gabapentinoids may offer benefits to cancer patients with 
pain but careful titration and monitoring of adverse effects is necessary. 
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Introduction 
  
The prevalence of pain in patients with cancer is over 50% [1]. Pain is often of moderate-to-severe 
intensity [2] and can be related to the tumour itself, cancer treatments or comorbid conditions [3]. 
The World Health Organisation 3-step analgesic ladder recommends the use of escalating analgesics 
(non-opioids to mild then strong opioids) with the use of adjuvants at each stage to achieve optimal 
pain control [4]. 
 
Gabapentinoids (gabapentin and pregabalin) are a type of adjuvant and anti-epileptic. They bind to 
the ɲ ?ɷƐƵďƵŶŝƚŽĨƉre-synaptic N, P/Q type voltage-gated calcium channels [5] in the spinal dorsal 
horn [6], causing reduced cell-surface expression [7], and subsequent reduction in calcium influx and 
neurotransmitter release [6, 8]. ɲ ?ɷ subunits upregulation has been found in neuropathic pain and 
persistent inflammatory states [9, 10, 11]. Gabapentinoids also affect descending inhibitory 
pathways by reducing GABA transmission in the locus coeruleus [6, 12, 13]. Table 1 provides further 
details about their pharmacokinetics and information for prescribing.  
 
Gabapentinoids have an established evidence base for use in the treatment of non-cancer 
neuropathic pain, including diabetic neuropathy, post-herpetic neuralgia and central neuropathic 
pain, comparable with antidepressants [15, 16, 17, 18, 19, 20, 21]. Recent Cochrane reviews of the 
management of neuropathic pain and gabapentinoids demonstrate a lack of studies investigating 
their use in cancer pain. No studies were identified for pregabalin use in acute and chronic pain in 
adults with cancer neuropathic pain [20]. Only three studies related to cancer pain management in a 
systematic review evaluating gabapentin in the management of chronic neuropathic pain in adults 
[21]. 
 
We have included evidence for the use of gabapentinoids in tumour- and treatment-related cancer 
pain in adult patients, focusing on randomised controlled trials (RCTs) within the last five years to 
demonstrate the most recent and highest quality of evidence. We have only included English-
language papers.  
 
Tumour-related pain 
 
The specific nature of pain is not always well-defined but most studies involve neuropathic or bone 
pain. Gabapentinoids have largely been evaluated in combination with other analgesics but a few 
studies evaluate their use as monotherapy. For the purposes of this review, monotherapy was 
defined as the use of gabapentin/pregabalin alone with no other regular analgesic, adjuvant or 
ĚŝƐĞĂƐĞŵŽĚŝĨǇŝŶŐƚƌĞĂƚŵĞŶƚ ?^ƚƵĚŝĞƐĂůůŽǁŝŶŐ ‘ĂƐƌĞƋƵŝƌĞĚ ?ƐŚŽƌƚ-acting opioids as rescue 
medication were still classified as monotherapy studies as the overall daily consumption is often 
inconsistent and poorly defined. Combination therapy was defined as the use of 
gabapentin/pregabalin in combination with an alternative analgesic, adjuvant or disease modifying 
treatment. Controls were either placebo, an alternative analgesic, adjuvant or disease modifying 
treatment. Table 2 summarises and provides further detail about included tumour-related pain 
studies.  
 
Monotherapy studies 
 
In their open-label study, Raptis et al [22] identified 120 patients with moderate-severe neuropathic 
cancer pain (NCP), uncontrolled on mild opioids. 60 patients were randomised to pregabalin and 60 
patients to transdermal fentanyl. 73.3% of the pregabalin group achieved at least a 30% reduction in 
the visual analogue score (VAS) for pain, in comparison to 36.7% in the fentanyl group (p<0.0001). 
Other statistically significant outcomes in favour of pregabalin were mean change in VAS score from 
baseline and final VAS score. This study shows some evidence of the benefit of pregabalin over 
fentanyl. It included patients with chemotherapy-induced neuropathy and tumour-related pain and 
the extent to which findings can be extrapolated to either group is unknown.  
 
Mishra et al [23] compared pregabalin with gabapentin, amitriptyline and placebo in groups of 30 
patients with severe NCP for 4 weeks. Results favoured pregabalin over all other groups with a 
reduction in mean VAS score from 7.77 to 2.5, and significantly lower scores in comparison with 
amitriptyline by week 3, and gabapentin and placebo by week 4. Scores were comparable at baseline 
and final VAS scores were 3.07, 3.23 and 3.4 for gabapentin, amitriptyline and placebo respectively. 
The pregabalin group also showed the greatest improvements in dysesthesia, burning and 
lancinating pain (statistically significant), but not allodynia. Gabapentin showed favourable 
outcomes over amitriptyline and placebo for burning and lancinating pain. However, there was no 
comparison of the differences between baseline and final outcomes. Therefore, the data is limited 
and it is unclear if pregabalin is superior.   
 
Combination therapy studies 
 
RCTs have evaluated gabapentinoids in combination with opioids alone, and opioids in conjunction 
with both radiotherapy and antidepressants.  
 
Combination with opioids alone 
 
In 2004 Caraceni et al [24] reported on the first placebo-controlled study of gabapentin in 
combination with opioids for NCP. 79 patients received gabapentin and 41 patients received placebo 
over 10 days. Both groups had comparable and stable opioid dosing (~100mg/day oral morphine 
equivalent). Gabapentin combined with opioid showed lower global pain scores compared to 
placebo (4.6 vs. 5.4 respectively on 0-10 numerical rating scale (NRS)). The proportion of patients 
with A?33% reduction in pain showed more responders in the gabapentin group on day one (24% 
versus 15%), however, by day five the group differences converged. There were no differences in 
common neuropathic pain symptoms and signs reported between the groups. In the Gabapentin 
group, 70% of patients required the maximum daily dose (1800mg), and one third still reported 
pain >5/10 on the final follow-up day. Although there is some evidence of additional benefit using 
gabapentin-opioid combination therapy, it may be minimal and may be offset by drug-related 
adverse events.  
 
In 2007, Keskinbora et al [25] conducted an open label study of gabapentin for NCP. 75 patients 
were randomised to receive gabapentin plus opioid or to continue on opioid therapy alone. The 
authors reported significantly lower mean pain scores after 2 weeks (compared to baseline) for both 
groups; however, the drop in pain scores was significantly greater for the gabapentin plus opioid 
group. In contrast to Caraceni et al. [24], Keskinbora et al. [25] demonstrated a clear therapeutic 
effect of gabapentin when used in combination with 140mg/day oral morphine equivalent dose.  
 
In an open-label study, Mercadante et al [26] compared opioid monotherapy to a combination of 
opioid and adjuvant pregabalin in 70 advanced cancer patients with unclassified cancer pain. Over 
an eight week follow-up period there were no differences in pain intensity, medication side-effects, 
pain interference with daily activities or quality of life between the two groups. The authors 
concluded that their flexible approach to dosing pregabalin, the small sample and between group 
heterogeneity (pain aetiology and pain mechanisms) may account for the negative findings. 
Nevertheless, the doses of pregabalin used were much lower than other pregabalin studies and may 
reflect cautious prescribing.  
 
Garassino et al [27] compared two escalating strategies for pregabalin and oxycodone combination 
therapy for NCP in a multicentre RCT. 38 patients were allocated to fixed oxycodone dose with 
increasing titration of pregabalin (Group A); and 37 patients were allocated to fixed pregabalin dose 
with increasing titration of oxycodone. Follow-up was 2 weeks, after which 77% of patients in Group 
A achieved at least 33% reduction in pain intensity (compared to baseline) versus 64% in Group B. 
The difference was not significant. There were fewer side effects and rescue doses for breakthrough 
pain reported in Group A. The authors concluded that both titration strategies resulted in adequate 
pain relief, and indicated a preference for a pregabalin titration strategy (Group A), reasonable given 
the secondary outcomes.  
 
Sjolund et al [28] compared flexible-dose pregabalin with placebo, both in combination with stable 
opioid therapy in 152 patients with cancer-induced bone pain (CIBP). After 28 days follow-up the 
mean change from baseline in worst pain score favoured pregabalin over placebo (-1.53 vs -1.23). 
There were similar changes in average pain and sleep interference in favour of pregabalin. The 
frequency of side effects was higher in the pregabalin group compared to the placebo group. The 
authors did not undertake statistical comparisons due to early termination of the trial due to 
positive effects in the pregabalin-opioid combination arm. Therefore, definitive conclusions cannot 
be drawn.  
 
In 70 cancer patients with unspecified severe pain, Chen et al [29] randomised patients to receive 
gabapentin in combination with oxycodone, or oxycodone alone. The authors describe the primary 
outcome pain intensity on 0-100mm VAS but no data are reported in the results. Baseline daily 
average oxycodone doses (DAOD) were not reported; however at week 1 follow-up the DAOD was 
23.4 mg/d and 25.3 mg/d for intervention and control groups respectively. Between group 
differences in DAOD were not significant at week 1 or 1 month follow-up but were significantly 
different (in favour of gabapentin) at 3 and 6 month follow-ups. Nevertheless, poor reporting of 
outcome measures and their results prevents meaningful interpretation of the study findings which 
should be interpreted with caution. 
 In a crossover study, Dou et al [30] evaluated the efficacy of pregabalin in combination with 
morphine. 40 patients with severe NCP were randomised to receive pregabalin-morphine 
combination followed by morphine-placebo combination, or vice versa. The two week treatment 
periods were separated by a one week washout period. Mean minimally effective morphine dose 
was significantly lower during the pregabalin-morphine combination period (184.4 ± 69.9 mg/day) 
compared to the placebo-morphine combination period (228.7 ± 66.9 mg/day), with greater 
improvements in sleep and reduction in constipation (both significant) but higher rates of dry mouth 
and drowsiness. The authors concluded that equivalence pain relief can be achieved with lower dose 
of morphine following the addition of pregabalin treatment.  
 
Other combination therapies 
 
Arai et al [31] compared low-dose gabapentin in combination with imipramine, with low-dose 
gabapentin, high-dose gabapentin, and imipramine, all in combination with opioids in 52 patients 
with NCP. Some patients in all groups continued regular NSAIDs. The gabapentin/imipramine/opioid 
group ?Ɛfinal total pain score was significantly lower than both the low-dose gabapentin/opioid and 
imipramine/opioid groups alone, but not the high-dose gabapentin/opioid group. However, the 
sample sizes were very small (n of 12-14), NSAID/varying opioid use may have confounded the 
result, and 7 days of follow-up is unlikely to be sufficient to demonstrate full effect. There is 
insufficient evidence to support one intervention over another.   
 
In their open-label RCT, Banerjee et al [32] evaluated gabapentin in combination with tramadol 
versus amitriptyline and tramadol in 88 patients with NCP over 6 months. Patients were excluded 
during the study if they used a stronger opioid. No statistical differences in VAS pain score, 
percentage of pain relief and global pain score were found throughout the study period. Both groups 
improved overall with VAS score, with the most significant improvements in the first month however 
this is difficult to interpret without further information about the titration schedule. This study 
shows no benefit of gabapentin over amitriptyline when used in combination with tramadol. It is 
unclear if the findings can be extrapolated to populations requiring stronger opioids.   
 
In 2016, Fallon et al [33ඵ], recruited 233 patients scheduled for radiotherapy with moderate-severe 
CIBP in 5 cancer centres. 116 patients were randomised to pregabalin and 117 patients to placebo, 
both in combination with palliative radiotherapy and a regular opioid, for 4 weeks. There was no 
difference between proportion of each group achieving treatment response (defined as a reduction 
ŽĨA? ?ƉŽŝŶƚƐŝŶǁŽƌƐƚƉĂŝŶ NRS from baseline, and stable/reduced opioid dose), average and worst 
pain, pain intensity and interference or number of breakthrough episodes. The study was 
underpowered given the dropout of study participants, and opioid use between groups was poorly 
described. However, this is an otherwise well conducted study showing no evidence of additional 
benefit with pregabalin.  
 
Nishihara et al [34] also evaluated the use of pregabalin as a combination therapy in CIBP. 12 
patients were randomised to high-dose pregabalin (group 1). The two comparator groups had 
pregabalin at a lower dose with group 2 (12 patients) also given imipramine, and group 3 (13 
patients) also given mirtazapine. All patients were given a regular opioid, an NSAID and a 
bisphosphonate. Some patients in each group were also given paracetamol. Groups 2 and 3 both had 
statistically significant reductions in total pain score and daily paroxysmal pain episodes in 
comparison with the group 1 throughout the study period of 7 days. However, as the sample sizes 
are small with very short follow-up, the findings may not demonstrate the full effect. Therefore this 
ƐƚƵĚǇ ?ƐĨindings are inconclusive regarding the role of gabapentinoids in combination with 
antidepressants.  
 
Treatment-related pain 
 
Gabapentin and pregabalin have both been evaluated in RCTs to prevent or manage treatment-
related cancer pain. In this section, treatment-related pains are defined as pains arising from specific 
cancer treatments such as chemotherapy and radiotherapy. Table 3 summarises and provides 
further detail about included treatment-related pain studies. We have not discussed cancer surgery 
and post-operative pain due to the crossover with mechanisms of pain in non-cancer post-operative 
pain. A recent systematic review evaluating the use of pre-operative gabapentinoids in patients 
undergoing breast cancer surgery found improvements in acute post-operative pain in comparison 
with patients receiving placebo/active controls [35]. 
 
Gabapentin studies 
 
Rao et al [36] used a cross-over study to compare gabapentin with placebo in chemotherapy-
induced neuropathic pain over a 3 week duration. No significant differences were found between 
gabapentin and placebo. However, the study was underpowered. Furthermore, eligible patients 
were those with pain, sensory loss or paraesthesia. This approach might have lacked sensitivity to 
detect any analgesic efficacy. 
 
Kataoka et al [37] evaluated the effect of gabapentin or placebo added to opioids and paracetamol 
in 22 patients with head and neck cancer with mucositis as a result of chemo-radiotherapy. Higher 
pain scores and opioid doses were found in the gabapentin arm but these were not significantly 
different from placebo. This was partly a feasibility study enabling data collection for future sample 
size calculations. It is very unlikely that the study was powered well enough to detect a possible 
difference. 
 
Pregabalin studies  
 
The effectiveness of pregabalin in preventing oxaliplatin-induced painful neuropathy was evaluated 
by de Andrade et al [38]. Of 199 colorectal cancer patients who were pain free and chemotherapy 
naiive randomised, 56 were subsequently excluded from analysis. Of those that were analysed, 78 
received pregabalin and 65 received control 3 days before and 3 days after each oxaliplatin infusion. 
Follow up lasted up to 6 months post chemotherapy. Average pain intensity and neuropathic pain 
symptoms assessed using the Douleur Neuropathique-4 (DN4) and the Neuropathic pain Symptom 
Inventory showed no differences between groups. This was corroborated by nerve conduction 
studies which also failed to show any protective effect of pregabalin.  
 
Another smaller study evaluating the protective effects of pregabalin was conducted by Shinde et al 
[39]. Patients who were about to receive paclitaxel chemotherapy were randomised to pregabalin or 
placebo. Forty six patients were recruited and no differences in pain intensity were found between 
arms.  
 
Conclusion  
 
For tumour-related pain, 10 out of 13 studies showed statistically significant benefits in favour of 
gabapentinoids. When used, as part of monotherapy or combination therapy, benefits were 
observed in 5 out of 6 studies evaluating gabapentin, and in 6 out of 8 studies evaluating pregabalin. 
For treatment-related pain, none of the 4 studies (2 gabapentin, 2 pregabalin) showed statistically 
significant benefits in favour of gabapentinoids. Unfortunately many of the studies included were 
limited by small sample size, lack of blinding and inadequate follow-up, considering the need to 
titrate treatments. This review is in agreement with systematic reviews within the last 5 years [40, 
41, 42, 43, 44]. More and better quality studies are required, although this may be challenging to 
accomplish in this patient population. Gabapentinoids may offer benefits to cancer patients with 
pain but careful titration and monitoring of adverse effects is necessary. 
 
Key points 
 
x Gabapentinoids act by reducing pain transmission in spinal pathways and modulating central 
descending inhibitory pathways.  
x Statistically significant benefits using gabapentinoids as monotherapy or as part of 
combination therapies for tumour-related cancer pain have been found. 
x Many existing RCTs have poor methodology due to small sample size, lack of blinding and 
insufficient follow-up to demonstrate full effect of interventions.  
x More RCTs of better quality are needed, although this may be challenging to accomplish in 
this patient population. 
x Gabapentinoids may offer benefits to cancer patients with pain but careful titration and 
monitoring of adverse effects is necessary. 
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